Bicara Therapeutics Inc. (BCAX): Total Liabilities
$29.54M
As of 2025-12-31
$43.48M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $29.54M | +63.0% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $18.12M | +17.1% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $15.47M | n/a | 2025-03-27, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Bicara Therapeutics Inc. (BCAX) | 2025-12-31 | $29.54M | +63.0% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $243.49M | +27.3% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $41.92M | +370.4% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $119.95M | +388.8% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $65.98M | +55.1% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $37.28M | +90.4% |
| Alumis Inc. (ALMS) | 2025-12-31 | $110.64M | +36.8% |
| Biohaven Ltd. (BHVN) | 2025-12-31 | $399.38M | +108.4% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $24.53M | -20.9% |
Compare BCAX, ARQT, BGM, MLTX side by side · Screen every company in Pharmaceutical Preparations ↗